Sarissa Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Sarissa Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500,356	Closed	-$128K	–	12
2023 Q1	$128K	Hold	500,356	–	–	0.02%	11
2022 Q4	$590K	Hold	500,356	–	–	0.07%	10
2022 Q3	$1.02M	Hold	500,356	–	–	0.12%	10
2022 Q2	$771K	Hold	500,356	–	–	0.08%	10
2022 Q1	$2.53M	Hold	500,356	–	–	0.24%	10
2021 Q4	$3.1M	Buy	+500,356	New	+$4.47M	0.27%	10

Sarissa Capital Management's PEAR Position: Q2 2023 in Review

Sarissa Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 500,356 shares — an estimated $128K sold.

Sarissa Capital Management first reported a position in PEAR in Q4 2021 and held it in 6 quarters. The position peaked at $3.1M in Q4 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Sarissa Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Sarissa Capital Management sold 500,356 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $128K.
Sarissa Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 6 quarters.
Sarissa Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $3.1M in Q4 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Sarissa Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.